公开(公告)号：US08830890B2

公开(公告)日：2014-09-09

申请号：US13387422

申请日：2012-01-18

申请人： Ying Sun ,  Kristina Jersenius

发明人： Ying Sun ,  Kristina Jersenius

IPC分类号： H04W52/02

CPC分类号： H04W52/0212 ,  H04W52/0222 ,  Y02D70/23 ,  Y02D70/24

摘要： The present invention relates to a method and device (15) for scheduling transmission of queued data packets of at least one terminal (11, 12, 13). To this end, information indicating packet queue time and queue buffer size is acquired. Further, it is determined, for each queue of the at least one terminal, whether either estimated data packet delay for any queued data packet exceeds a delay threshold value or whether number of data packets queued exceeds a buffer size, and if so, the data packets of each queue is scheduled for transmission from the at least one terminal as a respective single bundle of data.

摘要翻译： 本发明涉及一种用于调度至少一个终端（11,12,13）的排队数据分组传输的方法和装置（15）。 为此，获取指示分组队列时间和队列缓冲器大小的信息。 此外，对于至少一个终端的每个队列，确定任何排队的数据分组的估计数据分组延迟是否超过延迟阈值或者排队的数据分组的数量是否超过缓冲器大小，如果是，则数据 调度每个队列的分组作为相应的单个数据包从至少一个终端发送。

公开(公告)号：US08809264B2

公开(公告)日：2014-08-19

申请号：US11768723

申请日：2007-06-26

申请人： Deqiang Niu ,  Dong Liu ,  Joel D. Moore ,  Guoyou Xu ,  Ying Sun ,  Yonghua Gai ,  Datong Tang ,  Yat Sun Or ,  Zhe Wang

发明人： Deqiang Niu ,  Dong Liu ,  Joel D. Moore ,  Guoyou Xu ,  Ying Sun ,  Yonghua Gai ,  Datong Tang ,  Yat Sun Or ,  Zhe Wang

IPC分类号： A61K38/00 ,  C07D245/04 ,  A61K38/21 ,  C07D403/12

CPC分类号： C07D245/04 ,  A61K38/212 ,  A61K38/215 ,  C07D403/12 ,  A61K2300/00

摘要： The present invention relates to compounds, including compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

摘要翻译： 本发明涉及包括式I化合物或其药学上可接受的盐，酯或前药的化合物，其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

公开(公告)号：US08797983B2

公开(公告)日：2014-08-05

申请号：US13343992

申请日：2012-01-05

申请人： Ying Sun

发明人： Ying Sun

IPC分类号： H04W4/00

CPC分类号： H04W72/1221 ,  H04W72/1231 ,  Y02D70/1242 ,  Y02D70/1262

摘要： Methods for allocating spectrum resources among a plurality of devices in a wireless communication network are disclosed. In one aspect, an estimated number of resource blocks required by a first device and an estimated number of resource blocks required by a second device are determined. The required number of resource blocks may be determined by considering the number of resource blocks that would be necessary to empty the buffer of a first device and/or determining the number of resource blocks that would be sufficient to cause the first device to become power limited. These estimates may then be used to calculate first and second utilization weights, which can in turn be used to calculate scheduling entity weights for a plurality of scheduling entities, such as UEs in the communication network. Allocation may be based on the scheduling entity weights, utilization weights, and/or the required number of resource blocks.

摘要翻译： 公开了在无线通信网络中的多个设备之间分配频谱资源的方法。 在一个方面，确定第一设备所需的资源块的估计数量和第二设备所需的资源块的估计数量。 可以通过考虑清空第一设备的缓冲器所需的资源块的数量和/或确定足以使第一设备变得功率受限的资源块的数量来确定所需数量的资源块 。 然后可以使用这些估计来计算第一和第二利用权重，这又可以用于计算多个调度实体（例如通信网络中的UE）的调度实体权重。 分配可以基于调度实体权重，利用权重和/或所需数量的资源块。

公开(公告)号：US08660083B2

公开(公告)日：2014-02-25

申请号：US12989670

申请日：2008-04-28

申请人： Krister Norlund ,  Kelvin Maliti ,  Anders Persson ,  Ying Sun

发明人： Krister Norlund ,  Kelvin Maliti ,  Anders Persson ,  Ying Sun

IPC分类号： H04W72/14

CPC分类号： H04L1/1887 ,  H04L1/1812 ,  H04W72/1247 ,  H04W72/1252

摘要： A method (1000) for scheduling uplink transmission resources such as transmission duration and frequency to users (120) in a cell (110) of a cellular system (100). Grants for the use of uplink transmission resources are sent (1005) on a downlink control channel to users in the cell and the users' uplink transmissions are sent (1010) in subframes which have a certain extension in time and frequency. For each of at least a number of subframes, a decision (1015) is made on the number of users that will be scheduled resources for uplink transmission in the subframe, so that said number of users is maximized (1020) with respect to the control channel's capacity to transmit uplink grants for that subframe.

摘要翻译： 一种用于向蜂窝系统（100）的小区（110）中的用户（120）调度诸如传输持续时间和频率的上行链路传输资源的方法（1000）。 在下行链路控制信道上发送用于上行链路传输资源的授权（1005）给小区中的用户，并且在时间和频率上具有一定扩展的子帧中发送（1010）用户的上行链路传输（1010）。 对于至少多个子帧中的每一个，对子帧中将被用于上行链路传输的调度资源的用户数量做出决定（1015），使得所述用户数相对于控制被最大化（1020） 信道发送该子帧的上行链路许可的能力。

公开(公告)号：US20130343321A1

公开(公告)日：2013-12-26

申请号：US14003359

申请日：2011-03-11

申请人： Björn Nordström ,  Ying Sun

发明人： Björn Nordström ,  Ying Sun

IPC分类号： H04W72/08

CPC分类号： H04W72/085 ,  H04W24/00 ,  H04W48/16 ,  H04W72/1226 ,  H04W88/08

摘要： A radio base station and a method therein are provided for scheduling a radio resource to a user equipment. The radio base station estimates a first channel quality and determines a pathloss between the user equipment and the serving radio base station and a gain based on the pathloss. The radio base station also obtains a gain of the user equipment towards of neighbouring radio base stations, and determines a fraction of the determined pathloss, based on the gain and the obtained gains. The radio base station further determines a second channel quality of the channel based on the estimated first channel quality, the determined fraction and the determined pathloss to be compensated for; and schedules a radio resource for the user equipment based on the determined second channel quality.

摘要翻译： 提供无线基站及其方法，用于向用户设备调度无线资源。 无线基站估计第一信道质量并确定用户设备与服务无线基站之间的路径损耗以及基于路径损耗的增益。 无线电基站还获得朝向相邻无线电基站的用户设备的增益，并且基于增益和获得的增益来确定所确定的路径损耗的一部分。 无线电基站还基于所估计的第一信道质量，确定的分数和所确定的待补偿的路径损耗来确定信道的第二信道质量; 并基于所确定的第二信道质量为用户设备调度无线电资源。

公开(公告)号：US08547917B2

公开(公告)日：2013-10-01

申请号：US12935025

申请日：2008-03-28

申请人： Ying Sun ,  Christian Skärby ,  Gunnar Peters ,  Kelvin Maliti ,  Krister Norlund

发明人： Ying Sun ,  Christian Skärby ,  Gunnar Peters ,  Kelvin Maliti ,  Krister Norlund

IPC分类号： H04W4/00

CPC分类号： H04W72/1242 ,  H04W72/1289

摘要： A node of a radio access network includes a transceiver and a radio resource control unit. The transceiver is configured to facilitate communication with plural wireless terminals over a radio interface including transmissions on an uplink from the wireless terminals to the node and transmissions on a downlink from the node to the wireless terminals.The radio resource control unit configured to perform radio resource control functionality including layer three (L3) signaling between the node and the wireless terminals. The radio resource control unit includes an uplink scheduler configured to predict transmission of an uplink L3 message from the wireless terminals to the node and, for a particular wireless terminal, to generate, for transmission on the downlink, a grant message which in accordance with the prediction prioritizes a predicted L3 message of the particular wireless terminal relative to messages of others of the plural wireless terminals.

摘要翻译： 无线电接入网络的节点包括收发机和无线电资源控制单元。 收发器被配置为促进通过无线电接口与多个无线终端的通信，包括在从无线终端到节点的上行链路上的传输和在从节点到无线终端的下行链路上的传输。 所述无线资源控制部被配置为执行包括所述节点与所述无线终端之间的第三层（L3）信令的无线资源控制功能。 无线电资源控制单元包括上行链路调度器，被配置为预测来自无线终端的上行链路L3消息的传输到节点，并且对于特定的无线终端，为了在下行链路上的传输而生成根据 预测将特定无线终端的预测L3消息相对于多个无线终端中的其他消息的优先级排序。

公开(公告)号：US08304385B2

公开(公告)日：2012-11-06

申请号：US12270963

申请日：2008-11-14

申请人： Ying Sun ,  Dong Liu ,  Yat Sun Or ,  Zhe Wang

发明人： Ying Sun ,  Dong Liu ,  Yat Sun Or ,  Zhe Wang

IPC分类号： A61K38/00 ,  A61K31/33 ,  A61K38/12 ,  C07K5/08 ,  C07D513/00 ,  C07D245/00

CPC分类号： C07K5/0808 ,  A61K38/212 ,  A61K38/215 ,  C07K5/0812 ,  A61K2300/00

摘要： The present invention relates to compounds of Formula I, II, III or IV, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

摘要翻译： 本发明涉及式I，II，III或IV化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

公开(公告)号：US08268777B2

公开(公告)日：2012-09-18

申请号：US12327453

申请日：2008-12-03

申请人： Ying Sun ,  Deqiang Niu ,  Guoyou Xu ,  Yat Sun Or ,  Zhe Wang

发明人： Ying Sun ,  Deqiang Niu ,  Guoyou Xu ,  Yat Sun Or ,  Zhe Wang

IPC分类号： A61K38/00

CPC分类号： C07D245/04

摘要： The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

摘要翻译： 本发明涉及式I化合物或其药学上可接受的盐，酯或前体药物：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

公开(公告)号：US08268776B2

公开(公告)日：2012-09-18

申请号：US12016643

申请日：2008-01-18

申请人： Ying Sun ,  Deqiang Niu ,  Guoyou Xu ,  Yat Sun Or ,  Zhe Wang

发明人： Ying Sun ,  Deqiang Niu ,  Guoyou Xu ,  Yat Sun Or ,  Zhe Wang

IPC分类号： A61K38/00

CPC分类号： C07K5/0804 ,  C07K5/0812 ,  C07K7/06

摘要： The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

摘要翻译： 本发明公开了式I化合物或其药学上可接受的盐，酯或前药：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。

公开(公告)号：US08222203B2

公开(公告)日：2012-07-17

申请号：US12333457

申请日：2008-12-12

申请人： Ying Sun ,  Yonghua Gai ,  Yat Sun Or ,  Zhe Wang

发明人： Ying Sun ,  Yonghua Gai ,  Yat Sun Or ,  Zhe Wang

IPC分类号： A61K38/00

CPC分类号： C07K5/0812 ,  A61K38/00 ,  C07K5/06165

摘要： The present invention relates to compounds of Formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising a compound of the present invention.

摘要翻译： 本发明涉及式I化合物或其药学上可接受的盐，酯或前体药物：其抑制丝氨酸蛋白酶活性，特别是丙型肝炎病毒（HCV）NS3-NS4A蛋白酶的活性。 因此，本发明的化合物干扰丙型肝炎病毒的生命周期，也可用作抗病毒剂。 本发明还涉及药物组合物，其包含用于给患有HCV感染的受试者施用的上述化合物。 本发明还涉及通过施用包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。